)
Edge
Extra Everything: The Story of Chipotle
Chipotle's story from a single restaurant to a nationwide chain, through crisis and turnaround, built on one of the strongest models in the industry.
MedinCell
MedinCell (MEDCL) investor relations material
MedinCell R&D Day 2026 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.R&D Day 2026 summary12 May, 2026
Pipeline overview and program updates
UZEDY, a risperidone LAI, is demonstrating strong adoption in a competitive market, validating the platform approach.
Olanzapine LAI is awaiting regulatory approval, with a differentiated safety profile and significant market potential.
The pipeline includes both internal and external programs, with a focus on schizophrenia and expansion into other therapeutic areas.
Six LAI programs are prioritized under the AbbVie collaboration, with the first expected to enter clinical studies soon.
Clinical trial data and development milestones
UZEDY's clinical data show immediate onset of action and improved patient/physician adoption due to ease of use.
Olanzapine LAI demonstrated no PDSS events in ~4,000 injections, addressing prior safety concerns.
BEPO Star platform may enter clinical trials in 2028, with commercial launch targeted for 2033.
R&D strategy and innovation priorities
R&D is focused on platform expansion, risk reduction, and accelerating development through automation and data-driven approaches.
Platform innovation includes BEPO, BEPO Star, and next-gen technologies, each expanding formulation capabilities and adoption.
Complementary innovation targets API optimization, delivery devices, and external technology scouting.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from MedinCell
- UZEDY launch, AbbVie deal, and clinical progress drive strong financial and pipeline momentum.MEDCL
H2 23/242 Feb 2026 - UZEDY royalties and AbbVie deal drove revenue up 23%, but net loss widened on financial charges.MEDCLH1 24/2511 Jan 2026
- Strong product launches and partnerships position for profitability and €200M EBITDA by 2030.MEDCLH.C. Wainwright 27th Annual Global Investment Conference27 Dec 2025
- 50% revenue growth, UZEDY® expansion, Olanzapine LAI NDA, and strong liquidity.MEDCLH1 25/2619 Dec 2025
- UZEDY and long-acting olanzapine are set for major growth, driven by clinical and market advances.MEDCLEvercore ISI 8th Annual HealthCONx Conference3 Dec 2025
- UZEDY's commercial success and expanding LAI pipeline fuel strong growth and future profitability.MEDCLTD Cowen 45th Annual Healthcare Conference2 Dec 2025
- Growth accelerates with UZEDY, olanzapine LAI, and global health programs driving innovation.MEDCLJefferies London Healthcare Conference 202519 Nov 2025
- Innovative injectables, strong sales, and major partnerships fuel growth and future royalties.MEDCLJefferies Global Healthcare Conference 202512 Nov 2025
- Revenue up 2.8x, losses halved, and strong growth from UZEDY and Olanzapine LAI.MEDCLH2 24/2512 Nov 2025
Next MedinCell earnings date
H2 25/2616 Jun, 2026
MedinCell
Next MedinCell earnings date
H2 25/2616 Jun, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
)
Frequently asked questions
Explore our global coverage